ACORQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ACORQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-12-15), Acorda Therapeutics's share price is $0.0135. Acorda Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-21.86. Hence, Acorda Therapeutics's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for Acorda Therapeutics's Price-to-Free-Cash-Flow or its related term are showing as below:
During the past 13 years, Acorda Therapeutics's highest Price-to-Free-Cash-Flow Ratio was 87.71. The lowest was 3.07. And the median was 14.35.
Acorda Therapeutics's Free Cash Flow per Share for the three months ended in Mar. 2024 was $-16.25. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-21.86.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 58.60% per year.
During the past 13 years, Acorda Therapeutics's highest 3-Year average Free Cash Flow per Share Growth Rate was 76.90% per year. The lowest was -9.00% per year. And the median was 54.70% per year.
The historical data trend for Acorda Therapeutics's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acorda Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Price-to-Free-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
Acorda Therapeutics Quarterly Data | ||||||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
Price-to-Free-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
For the Drug Manufacturers - Specialty & Generic subindustry, Acorda Therapeutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Acorda Therapeutics's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Acorda Therapeutics's Price-to-Free-Cash-Flow falls into.
Acorda Therapeutics's Price-to-Free-Cash-Flow ratio for today is calculated as
Price-to-Free-Cash-Flow Ratio | = | Share Price | / | Free Cash Flow per Share (TTM) |
= | 0.0135 | / | -21.86 | |
= | N/A |
Acorda Therapeutics's Share Price of today is $0.0135.
Acorda Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-21.86.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Price-to-Free-Cash-Flow Ratio | = | Market Cap | / | Free Cash Flow |
Acorda Therapeutics (OTCPK:ACORQ) Price-to-Free-Cash-Flow Explanation
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Thank you for viewing the detailed overview of Acorda Therapeutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Thomas M. Burns | director | 2910 SEVENTH STREET, BERKELEY CA 94710 |
Ron Cohen | officer: CEO and President | C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
John Varian | director | ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555 |
Michael A Gesser | officer: Chief Financial Officer | 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
Neil S. Belloff | officer: General Counsel | 11 RADNOR LANE, MAHOPAC NY 10541 |
Kerry M Clem | officer: Chief Commercial Officer | 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
Robert Morales | officer: Interim PAO & PFO | 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
Jane Wasman | officer: Exec V Pres, Gen Cnsl & Sec | C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
Lauren M Sabella | officer: Exec. VP-Commercial Dvlpmnt | C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
David Lawrence | officer: Chief Financial Officer | C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
Scopia Capital Management Lp | 10 percent owner | 152 WEST 57TH STREET, 33RD FLOOR, NEW YORK NY 10019 |
Lorin Randall | director | C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
Burkhard Blank | officer: Chief Medical Officer | C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
Scopia Management, Inc. | 10 percent owner | 152 WEST 57TH STREET, 33RD FLOOR, NEW YORK NY 10019 |
Matthew Sirovich | 10 percent owner | C/O SCOPIA MANAGEMENT INC, 450 SEVENTH AVENUE, 43RD FLOOR, NEW YORK NY 10123 |
From GuruFocus
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By Business Wire • 04-01-2024
By GuruFocus Research • 02-06-2024
By Business Wire • 03-25-2024
By Business Wire • 04-01-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.